These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

433 related items for PubMed ID: 14586718

  • 1. Effects of the angiotensin II type 1 receptor antagonist candesartan, compared with angiotensin-converting enzyme inhibitors, on the urinary excretion of albumin and type IV collagen in patients with diabetic nephropathy.
    Sato A, Tabata M, Hayashi K, Saruta T.
    Clin Exp Nephrol; 2003 Sep; 7(3):215-20. PubMed ID: 14586718
    [Abstract] [Full Text] [Related]

  • 2. Combination of half doses of angiotensin type 1 receptor antagonist and angiotensin-converting enzyme inhibitor in diabetic nephropathy.
    Fujisawa T, Ikegami H, Ono M, Nishino M, Noso S, Kawabata Y, Ogihara T.
    Am J Hypertens; 2005 Jan; 18(1):13-7. PubMed ID: 15691611
    [Abstract] [Full Text] [Related]

  • 3. Effects of candesartan, an angiotensin II type 1 receptor blocker, on diabetic nephropathy in KK/Ta mice.
    Liao J, Kobayashi M, Kanamuru Y, Nakamura S, Makita Y, Funabiki K, Horikoshi S, Tomino Y.
    J Nephrol; 2003 Jan; 16(6):841-9. PubMed ID: 14736011
    [Abstract] [Full Text] [Related]

  • 4. Effect of low-dose dual blockade of renin-angiotensin system on urinary TGF-beta in type 2 diabetic patients with advanced kidney disease.
    Song JH, Cha SH, Lee HJ, Lee SW, Park GH, Lee SW, Kim MJ.
    Nephrol Dial Transplant; 2006 Mar; 21(3):683-9. PubMed ID: 16330466
    [Abstract] [Full Text] [Related]

  • 5. Renal protection and angiotensin converting enzyme inhibition in microalbuminuric type I and type II diabetic patients.
    Cooper ME.
    J Hypertens Suppl; 1996 Dec; 14(6):S11-4. PubMed ID: 9023709
    [Abstract] [Full Text] [Related]

  • 6. [Angiotensin II type-1 receptor antagonists and diabetes mellitus].
    Schnack C, Schernthaner G.
    Wien Med Wochenschr; 2001 Dec; 151(7-8):165-8. PubMed ID: 11450165
    [Abstract] [Full Text] [Related]

  • 7. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [Abstract] [Full Text] [Related]

  • 8. Add-on angiotensin receptor blocker in patients who have proteinuric chronic kidney diseases and are treated with angiotensin-converting enzyme inhibitors.
    Kanno Y, Takenaka T, Nakamura T, Suzuki H.
    Clin J Am Soc Nephrol; 2006 Jul; 1(4):730-7. PubMed ID: 17699280
    [Abstract] [Full Text] [Related]

  • 9. Effect of combination therapy of angiotensin-converting enzyme inhibitor plus calcium channel blocker on urinary albumin excretion in hypertensive microalbuminuric patients with type II diabetes.
    Shigihara T, Sato A, Hayashi K, Saruta T.
    Hypertens Res; 2000 May; 23(3):219-26. PubMed ID: 10821130
    [Abstract] [Full Text] [Related]

  • 10. Angiotensin II type 1 receptor blockers reduce urinary oxidative stress markers in hypertensive diabetic nephropathy.
    Ogawa S, Mori T, Nako K, Kato T, Takeuchi K, Ito S.
    Hypertension; 2006 Apr; 47(4):699-705. PubMed ID: 16505207
    [Abstract] [Full Text] [Related]

  • 11. Effects of monotherapy of temocapril or candesartan with dose increments or combination therapy with both drugs on the suppression of diabetic nephropathy.
    Ogawa S, Takeuchi K, Mori T, Nako K, Tsubono Y, Ito S.
    Hypertens Res; 2007 Apr; 30(4):325-34. PubMed ID: 17541211
    [Abstract] [Full Text] [Related]

  • 12. The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-beta excretion in 2 groups of patients with IgA and diabetic nephropathy.
    Song JH, Lee SW, Suh JH, Kim ES, Hong SB, Kim KA, Kim MJ.
    Clin Nephrol; 2003 Nov; 60(5):318-26. PubMed ID: 14640237
    [Abstract] [Full Text] [Related]

  • 13. Possible role of VEGF in the progression of kidney disease in streptozotocin (STZ)-induced diabetic rats: effects of an ACE inhibitor and an angiotensin II receptor antagonist.
    Kakizawa H, Itoh Y, Imamura S, Matsumoto T, Ishiwata Y, Ono Y, Yamamoto K, Kato T, Hayakawa N, Oda N, Goto Y, Goto Y, Nagasaka A, Senda T, Itoh M.
    Horm Metab Res; 2004 Jul; 36(7):458-64. PubMed ID: 15305228
    [Abstract] [Full Text] [Related]

  • 14. [ACE inhibitors and early diabetic nephropathy].
    Bangstad HJ, Hartmann A, Berg TJ, Hanssen KF.
    Tidsskr Nor Laegeforen; 1995 Oct 10; 115(24):3039-41. PubMed ID: 7570536
    [Abstract] [Full Text] [Related]

  • 15. Angiotensin II receptor blocker and long-acting calcium channel blocker combination therapy decreases urinary albumin excretion while maintaining glomerular filtration rate.
    Nakagawa N, Fujino T, Kabara M, Matsuki M, Chinda J, Kikuchi K, Hasebe N, NICE-Combi Study Group.
    Hypertens Res; 2011 Oct 10; 34(10):1121-6. PubMed ID: 21796123
    [Abstract] [Full Text] [Related]

  • 16. Low-dose candesartan cilexetil prevents early kidney damage in type 2 diabetic patients with mildly elevated blood pressure.
    Murayama S, Hirano T, Sakaue T, Okada K, Ikejiri R, Adachi M.
    Hypertens Res; 2003 Jun 10; 26(6):453-8. PubMed ID: 12862201
    [Abstract] [Full Text] [Related]

  • 17. Comparative effect of lisinopril and lacidipine on urinary albumin excretion in patients with type 11 diabetic nephropathy.
    Salako BL, Finomo FO, Kadiri S, Arije A, Olatosin AO.
    Afr J Med Med Sci; 2002 Mar 10; 31(1):53-7. PubMed ID: 12518931
    [Abstract] [Full Text] [Related]

  • 18. Microalbuminuria reduction with telmisartan in normotensive and hypertensive Japanese patients with type 2 diabetes: a post-hoc analysis of The Incipient to Overt: Angiotensin II Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) study.
    Makino H, Haneda M, Babazono T, Moriya T, Ito S, Iwamoto Y, Kawamori R, Takeuchi M, Katayama S, INNOVATION Study Group.
    Hypertens Res; 2008 Apr 10; 31(4):657-64. PubMed ID: 18633177
    [Abstract] [Full Text] [Related]

  • 19. Is the reno-protective effect of valsartan dose dependent? A comparative study of 80 and 160 mg day(-1).
    Saikawa T, Sasaki J, Biro S, Kono S, Otonari T, Ikeda Y, DDV investigators.
    Hypertens Res; 2010 Sep 10; 33(9):886-91. PubMed ID: 20555331
    [Abstract] [Full Text] [Related]

  • 20. Effect of tranilast in early-stage diabetic nephropathy.
    Soma J, Sato K, Saito H, Tsuchiya Y.
    Nephrol Dial Transplant; 2006 Oct 10; 21(10):2795-9. PubMed ID: 16820373
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.